Tissue & cell · 2025
Ganoderic acid A alleviate psoriasis by inhibiting GSDMD-mediated pyroptosis.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Xiao Chenggen, Chen Junchen, Zhou Xingchen, Liu Hong
Аннотация
OBJECTIVE: Psoriasis is a chronic inflammatory dermatological condition characterized by the infiltration of inflammatory cells into the dermal layer. This study aimed to elucidate the anti-inflammatory properties and underlying molecular mechanisms of Ganoderic acid A in the treatment of psoriasis.
METHODS: A psoriasis model was induced in mice using IMQ to evaluate the effects of Ganoderic acid A in vivo. The Psoriasis Area and Severity Index (PASI) was employed to assess the severity of skin inflammation in the lesions. Techniques such as hematoxylin-eosin staining, RNA sequencing and immunofluorescence assays were utilized to evaluate the efficacy. Both in vivo and exvivo experiments were conducted to confirm the clinical relevance and explore the regulatory mechanisms involved.
RESULTS: The findings demonstrated that both intraperitoneal and topical applications of Ganoderic acid A alleviate psoriasis effectively. Specifically, Ganoderic acid A resulted in a reduction in skin thickness, erythema, scaling and the expression of inflammatory cytokines. Mechanistically, Ganoderic acid A was shown to reduce the secretion of skin inflammatory factors by inhibiting pyroptosis through the GSDMD pathway.
CONCLUSION: Ganoderic acid A exhibits potential as a therapeutic agent for psoriasis and may be considered for inclusion in dietary recommendations for patients.
METHODS: A psoriasis model was induced in mice using IMQ to evaluate the effects of Ganoderic acid A in vivo. The Psoriasis Area and Severity Index (PASI) was employed to assess the severity of skin inflammation in the lesions. Techniques such as hematoxylin-eosin staining, RNA sequencing and immunofluorescence assays were utilized to evaluate the efficacy. Both in vivo and exvivo experiments were conducted to confirm the clinical relevance and explore the regulatory mechanisms involved.
RESULTS: The findings demonstrated that both intraperitoneal and topical applications of Ganoderic acid A alleviate psoriasis effectively. Specifically, Ganoderic acid A resulted in a reduction in skin thickness, erythema, scaling and the expression of inflammatory cytokines. Mechanistically, Ganoderic acid A was shown to reduce the secretion of skin inflammatory factors by inhibiting pyroptosis through the GSDMD pathway.
CONCLUSION: Ganoderic acid A exhibits potential as a therapeutic agent for psoriasis and may be considered for inclusion in dietary recommendations for patients.